Mycobacterium riyadhense pulmonary infection, France and Bahrain.
|Article Type:||Letter to the editor|
Mycobacterial infections (Care and treatment)
Mycobacterial infections (Demographic aspects)
Lung diseases (Diagnosis)
Lung diseases (Care and treatment)
Lung diseases (Demographic aspects)
|Publication:||Name: Emerging Infectious Diseases Publisher: U.S. National Center for Infectious Diseases Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2012 U.S. National Center for Infectious Diseases ISSN: 1080-6040|
|Issue:||Date: Jan, 2012 Source Volume: 18 Source Issue: 1|
|Geographic:||Geographic Scope: Bahrain; France Geographic Name: Bahrain; France Geographic Code: 7BAHR Bahrain; 4EUFR France|
To the Editor: Mycobacterium riyadhense is a newly described
mycobacterial species that is potentially pathogenic for humans.
Extrapulmonary infection with this nontuberculous mycobacterium (NTM)
has been reported (1).We report 2 cases of pulmonary infection with this
The first case of infection was in a 39-year-old woman who was admitted to Toulon Military Hospital, Toulon, France, in December 2005 with suspected pulmonary tuberculosis. For 1 month, the patient had a persistent cough, fever, asthenia, and weight loss. Findings on chest radiographs were suggestive of tuberculosis, with cavitation in the right upper lobe, and the tuberculin skin test reaction was positive. Sputum specimens collected on 3 consecutive days were negative for acid-fast bacilli (AFB), but broth cultures (BacT/ALERT 3D system; bioMerieux, Marcy l'Etoile, France) yielded mycobacterial growth.
We used 4 multiplex line-probe assays to identify the mycobacteria: GenoType MTBC (Hain Lifescience, Nehren, Germany) identified the organisms as members of the M. tuberculosis complex (MTBC; with a nonspecific reaction, banding pattern 1, 2, 3); GenoType Mycobacterium CM (Common Mycobacteria) (Hain Lifescience) kit and GenoType Mycobacterium AS (Additional Species) (Hain Lifescience) kit identified the strains as members of the MTBC and as unspecified Mycobacterium species, respectively; and INNO-LiPA MYCOBACTERIA v2 (Innogenetics, Ghent, Belgium) yielded a Mycobacterium-positive reaction by genus probe but no species-specific result.
Following the criteria of the American Thoracic Society, we considered the isolates as the pathogens responsible for the patient's respiratory disease (2). The patient was treated with a combination of isoniazid (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide (PZA). EMB and PZA were continued for 2 months; INH and RIF were continued for 10 months (Table), at which time the patient was considered cured.
The second case of infection was in a 43-year-old man who was admitted to Awali Hospital, Awali, Bahrain, in November 2006. The patient reported malaise, insomnia, cough, weight loss, and anorexia. Radiographs showed features suggestive of tuberculosis (left upper lobe consolidation with focal cavitation). Sputum specimens collected on 3 consecutive days were positive for AFB and mycobacterial growth. To identify the pathogen(s), we used the same 4 mutiplex lineprobe assays as used for case-patient 1, and results were similar. The identified strain was considered to be the pathogen responsible for the respiratory disease (2).
The patient was treated with a combination of clarithromycin (CLR) and ciprofloxacin (CIP) for 12 months; however, he had a clinical and microbiological (i.e., positive for AFB and culture results with the same NTM) relapse during this treatment. In November 2007, 3 sputum specimens from the patient were positive for AFB, and cultures yielded a mycobacterial strain identical to that identified by the assays. The patient was treated with antituberculous drugs (INH, RIF, EMB, PZA, plus CLR and CIP) for 6 months, and then INH, RIF, CLR, CIP were continued for 2 additional months (Table), after which the patient showed clinical improvement.
In the 2 cases, molecular identification of the isolates as M. riyadhense was achieved by using partial hsp65 and rpoB gene sequencing, which was based on the high level of sequence identities with the type strain of M. riyadhense and a distance score of 3.5 and 4.6, respectively, to the next species, "M simulans" (Table). Broth microdilution panels (SLOMYCO Sensititer; Trek Diagnosis Systems, Cleveland, OH, USA) were used to determine drug susceptibility (Table) (3).
Commercial probes are frequently used for rapid identification of mycobacterial species (4); however, M. riyadhense and other recently proposed NTMs (e.g., M. kumamotonense and "M. simulans,y) cross-react with MTBC DNA probes and may be missed by line-probe assays (5,6). With the emergence of new NTM species, commercial probes could fail to discriminate between species, leaving clinical isolates either unidentified or misidentified. Because of its ease of use, accuracy, and discriminatory power, multilocus sequence analysis may soon become the standard for routine NTM species identification.
We have shown evidence for the pathogenic role of M. riyadhense in pulmonary diseases, a pathogen that has previously been reported to have extrapulmonary pathogenicity (1). Clinical and radiologic signs and symptoms of pulmonary infection caused by M. riyadhense, including cough, weight loss, fever, and cavitating lung lesions, were similar to those in typical cases caused by MTBC strains. van Ingen et al. (7) suggested that the region of difference 1 (RD1) virulence locus identified in MTBC members may also play a crucial role in virulence of some NTM species. These authors found RD1 genes in NTMs that were causing human disease, including M. kansasii, M. szulgai, M. marinum, and the type strain of M. riyadhense (7).
We confirmed the presence of RD1 esat-6 and cfp-10 genes in the M. riyadhense isolates reported here (GenBank accession nos. JF896090-JF896093). Because M. riyadhense is an emerging pathogen with, to our knowledge, only 1 previously reported extrapulmonary case of infection (1), the optimal treatment for infected patients is unknown. Our results and drug susceptibility testing indicate that antituberculous drugs, including INH, RMP, and EMB, are effective against M. riyadhense infection (Table), but the combination of CLR plus CIP was not effective in 1 case-patient reported here, despite in vitro susceptibility to both drugs.
We thank Isabelle Zorgniotti and Dominique Terru for excellent technical assistance and Laurent Lefrancois and the staff of the international department of Biomnis for performing laboratory tests.
The Institut de Recherche pour le Developpement, Centre National de la Recherche Scientifique, and Hopital Arnaud de Villeneuve provided financial and technical support.
(1.) van Ingen J, Al-Hajoj SA, Boeree M, Al-Rabiah F, Enaimi M, de Zwaan R, et al. Mycobacterium riyadhense sp. nov., a non-tuberculous species identified as Mycobacterium tuberculosis complex by a commercial line-probe assay. Int J Syst Evol Microbiol. 2009;59:1049-53. doi:10.1099/ijs.0.005629-0
(2.) Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of non-tuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367416. doi:10.1164/rccm.200604-571ST Erratum in Am J Respir Crit Care Med. 2007;175(7):744-5.
(3.) National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, Nocardiae, and other aerobic actinomycetes; approved standard. NCCLS document M24-A. Wayne (PA): The Committee; 2003.
(4.) Tortoli E, Nanetti A, Piersimoni C, Cichero P, Farina C, Mucignat G, et al. Performance assessment of new multiplex probe assay for identification of mycobacteria. J Clin Microbiol. 2001;39:1079-84. doi:10.1128/JCM.39.3.1079-1084.2001
(5.) Rodriquez-Aranda A, Jimenez MS, Yubero J, Chaves F, Rubio-Garcia R, Palenque E, et al. Misidentification of Mycobacterium kumamotonense as M. tuberculosis. Emerg Infect Dis. 2010;16:1178-80.
(6.) Tortoli E, Rogasi PG, Fantoni E, Beltrami C, De Francisci A, Mariottini A. Infection due to a novel mycobacterium, mimicking multidrug-resistant Mycobacterium tuberculosis. Clin Microbiol Infect. 2010;16:1130-4. doi:10.1111/j.1469 0691.2009.03063.x
(7.) van Ingen J, de Zwaan R, Dekhuijzen R, Boeree M, van Soolingen D. Region of difference 1 in nontuberculous Mycobacterium species adds a phylogenetic and taxonomical character. J Bacteriol. 2009;191:5865-7. doi:10.1128/JB.00683 09
Sylvain Godreuil, Helene Marchandin, Anne-Laure Michon, Mikael Ponsada, Georges Chyderiotis, Patrick Brisou, Abdul Bhat, and Gilles Panteix
Author affiliations: Institut National de la Sante et de la Recherche Medicale Unite 1058, Montpellier, France (S. Godreuil); Hopital Arnaud de Villeneuve, Montpellier (S. Godreuil, H. Marchandin, A.-L. Michon); Universite Montpellier 1, Montpellier (H. Marchandin, A.-L. Michon); Laboratoire Biomnis, Lyon, France (M. Ponsada, G. Chyderiotis, G. Panteix); Hopital d'Instruction des Armees Sainte-Anne, Toulon, France (P. Brisou); and Awali Hospital, Awali, Bahrain (A. Bhat)
Address for correspondence: Sylvain Godreuil, Centre Hospitalo-Universitaire, Hopital Arnaude Villeneuve, Laboratoire de Bacteriologie 371, Avenue du Doyen Gaston Giraud, Montpellier Cedex 5 34295, France; email: email@example.com
Table. Clinical characteristics, drug susceptibility testing, and outcome for 3 case-patients with Mycobacterium riyadhense infection, Saudi Arabia, France, and Bahrain * Molecular-based identification of M. riyadhense % Sequence similarity GenBank Patient Clinical with type accession age, y/sex situation Gene strain nos. 19/M Bone 16S rRNA, Type strain EU27464, ([dagger]) infection rpoB, hsp65 FJ786256, in left EU921671 maxillary sinus 39/F Pulmonary 16S rRNA 99.8, 99.8, JF896094, ([section]) infection ([paragraph]), 100 JF896096, rpoB, hsp65 JF896098 43/M ** Pulmonary 16S rRNA 99.8, 99.7, JF896095, infection ([paragraph]), 99.1 JF896097, rpoB, hsp65 JF896099 Drug susceptibility pattern, Patient drug (MIC, [micro]g/mL) age, y/sex interpretation 19/M AMK (10.0) R; CYC (20.0) S; ([dagger]) CIP (2.0) S; CLF (<0.5) S; CLR (<2.0) S; EMB (5.0) S; INH (1.0) I; PAS (>1.0) R; PRO (<1.0) S; RFB (0.2) S; RIF (0.2) S; STR (5.0) S ([dagger]) 39/F AMK ([less than or equal to] ([section]) 1.0) S; CIP (1.0) S; CLR (0.12) S; DOX (16.0) R; EMB ([less than or equal to] 0.5) S; ETH (0.3) S; INH (0.5) S; LZD ([less than or equal to] 1.0) S; MOX ([less than or equal to] 0.12) S; RFB ([less than or equal to] 0.25) S; RIF ([less than or equal to] 0.12) S; STR (1.0) S; TMP/SMX ([less than or equal to] 0.12/2.38) NA# 43/M ** AMK ([less than or equal to] 1.0) S; CIP (0.12) S; CLR (0.12) S; EMB ([less than or equal to] 0.5) S; ETH (0.3) S; DOX (4.0) R; INH (0.25) S; LZD ([less than or equal to] 1.0) S; MOX ([less than or equal to] 0.12) S; RFB ([less than or equal to] 0.25) S; RIF CIP; then INH, ([less than or equal to] 0.12) S; STR ([less than or equal to] 0.5) S; RFP, CLR, TMP/SMX ([less than or equal to] 2.0/38.0) NA# Treatment Patient Antimicrobial duration, age, y/sex drug therapy outcome 19/M INH, RFP, EMB; 9 mo, cured ([dagger]) then INH, RFP 39/F INH, RFP, EMB, 1 y, cured ([section]) PZA; then INH, RFP 43/M ** CLR, CIP; then 1 y, relapse; INH, RFP, EMB, 8 mo, cured PZA, CLR, CIP * AMK, amikacin; R, resistant; CYC, cycloserine; S, susceptible; CIP, ciprofloxacin; CLF, clofazimine; CLR, clarithromycin; EMB, ethambutol; INH, isoniazid; I, intermediate; PAS, para/ aminosalicylate sodium; PRO, prothionamide; RFB, rifabutin; RIF, rifampin; STR, streptomycin; RFP, rifapentine; DOX, doxycycline; ETH, ethionamide; LZD, linezolid; MOX, moxifloxacin; TMP/SMX, trimethoprim/sulfamethoxazole; NA, not available; PZA, pyrazinamide. ([dagger]) Patient in Saudi Arabia; reported by van Ingen et al. (1). ([double dagger]) Drug susceptibility testing was performed by using the agar dilution method. ([section]) Patient in France. ([paragraph]) Low 16S rRNA gene polymorphism between several mycobacterial species. # Drug susceptibility testing was performed by using broth microdilution panels (SLOMYCO Sensititer; Trek Diagnosis Systems, Cleveland< OH, USA) and interpreted according to standards of the National Committee for Clinical Laboratory Standards (3). ** Patient in Bahrain.
|Gale Copyright:||Copyright 2012 Gale, Cengage Learning. All rights reserved.|